However, there are still no clinical trial data available to guide practice, even when hormone receptor expression is negative.(3) Given the lack of studies on the use of HT in uterine sarcomas, it is not possible to determine the safety of its prescription in this group of tumors.(12) To date, other non-hormonal strategies should be indicated to address menopausal symptoms and prevent and treat osteoporosis.(12) The following guidelines are available for women survivors of endometrial cancer and uterine sarcoma:(1-3,12-15). Here, NR4A1 is linked to uterine corpus sarcoma.